CytoMed Therapeutics (GDTC) Assets Average (2023 - 2025)

CytoMed Therapeutics has disclosed Assets Average across 3 years of filings, most recently posting $7.3 million for Q4 2025.

• In Q4 2025, Assets Average fell 21.43% year-over-year to $7.3 million; the TTM figure through Dec 2025 stood at $7.3 million (down 21.43% YoY), while the FY2025 annual figure was $6.8 million, down 18.48% from the prior year.
• Assets Average came in at $7.3 million for Q4 2025 at CytoMed Therapeutics, down from $8.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $11.5 million in Q4 2023 to a low of $7.3 million in Q4 2025.
• Average Assets Average over 3 years is $9.1 million, with a median of $9.0 million recorded in 2023.
• Year-over-year, Assets Average increased 13.52% in 2024 and slipped 21.43% in 2025.
• Over 3 years, Assets Average stood at $11.5 million in 2023, then decreased by 19.92% to $9.2 million in 2024, then decreased by 21.43% to $7.3 million in 2025.
• Per Business Quant data, the three most recent Assets Average figures were $7.3 million in Q4 2025, $8.0 million in Q2 2025, and $9.2 million in Q4 2024.